Cancer diagnostics company Biomoda Inc. today announced it has signed an agreement with Obio, a corporation formed to pursue public and private funding for cancer research, to establish a CLIA-certified Biomoda clinical laboratory in Ohio to fuel ongoing research and development of Biomoda’s porphyrin-based assay for the detection of early-stage cancer.

Clinical Laboratory Improvement Amendments (CLIA) were implemented by Congress in 1988 and certified by the Department of Health and Human Services to set boundaries and regulations for laboratory testing to ensure accuracy and reliability of patient test results.

For Biomoda, the agreement will strengthen its partnership with Obio and give the company access to reputable and solid resources.

“We are ready to expand our strategic alliance with Obio to include operational facilities that will put us in closer contact with Ohio’s top-rated medical, scientific and technical resources,” Biomoda President John Cousins stated in the press release. “Ohio is proactively attracting promising biotech companies to the state through public initiatives that support research and commercialization. This fits perfectly with our strategic plan for taking CyPath(R) into the marketplace.”

Biomoda said that the laboratory formed in its partnership with Obio will employ trained technicians to prepare fluid and tissue samples for immersion into Biomoda’s CyPath labeling solution, as well as for subsequent ultraviolet screening.

Biomoda currently is conducting clinical trials of its CyPath to demonstrate it potential as an inexpensive, noninvasive assay designed to identify early-stage lung. The company is seeking Food and Drug Administration (FDA) approval of its screening technology as a Class III medical device. As of now, CyPath is only used for investigational purposes.

For more information on the company, visit